News >

CD19-Directed CAR-NK Cell Therapy Elicits Responses in Non-Hodgkin Lymphoma and CLL

Brittany Cote
Published: Thursday, Feb 13, 2020

Katy Rezvani, MD, PhD, a professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center

Katy Rezvani, MD, PhD

Treatment with a CD19-targeted CAR-natural killer (NK)–cell therapy led to a 73% objective response rate (ORR), including 7 complete responses (CRs), in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), according to results of a small phase I/IIa study (NCT03056339) published in the New England Journal of Medicine.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication